Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Role of Radium-223 in Treating mCRPC

April 21st 2022

Expert Scott Tagawa, MD, MS, FACP, details the role of radium-223 in treating metastatic CRPC and highlights real-world experiences.

Patient Factors in Selecting Therapy for mCRPC

April 21st 2022

Shared insight on the key factors that play into the selection of therapy for patients with metastatic castration-resistant prostate cancer.

Role of Micronized Abiraterone in Metastatic HSPC

April 20th 2022

Shared insight on the role of micronized abiraterone in metastatic HSPC and how it may be utilized in practice.

Overview of Treatment for Metastatic HSPC

April 20th 2022

Expert perspectives on metastatic hormone-sensitive prostate cancer and the current state of the treatment armamentarium.

Dr. Moon on the Role of PARP Inhibitors in Prostate Cancer

April 14th 2022

Helen Heng-Shan Moon, MD, discusses the role of PARP inhibitors in prostate cancer.

Metastatic CRPC Treatment Armamentarium

April 14th 2022

A detailed review of the available pharmacologic agents used to treat patients with metastatic castration-resistant prostate cancer.

Role of Novel Imaging in Prostate Cancer

April 14th 2022

A brief discussion on how novel imaging strategies are being used to inform the treatment of patients with prostate cancer.

FDA Authorizes IND Application for 177Lu-rhPSMA-10.1 for Metastatic Castration-Resistant Prostate Cancer

April 13th 2022

The FDA has cleared an investigational new drug application for 177Lu-rhPSMA-10.1 as a potential therapeutic option for patients with metastatic castration-resistant prostate cancer.

Monitoring Strategies in Nonmetastatic CRPC

April 13th 2022

A brief discussion on best practices in monitoring patients on therapy for nonmetastatic castration-resistant prostate cancer [nmCRPC].

Nonmetastatic Castration-Resistant Prostate Cancer: Quality of Life Measures

April 13th 2022

A brief review of the value of quality of life measures while managing patients on therapy for nonmetastatic castration-resistant prostate cancer (nmCRPC).

Dr. Tagawa on the Investigation of 225Ac-J591 and 177Lu-PSMA-I&T in mCRPC

April 12th 2022

Scott T. Tagawa, MD, MS, FACP, discusses the investigation of 225Ac-J591 and 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer in a phase 1/2 trial.

gLOH-High Status Is Associated With Enhanced Response to Talazoparib in mCRPC

April 11th 2022

High genomic loss of heterozygosity scores may serve as a predictive marker for response to treatment with talazoparib in metastatic castration-resistant prostate cancer.

Genetically Adjusting PSA May Improve Screening with PSA Alone in Prostate Cancer

April 11th 2022

The genetic adjustment of prostate-specific antigen could reduce over-diagnosis, de-escalate invasive testing, and improve the detection of aggressive disease in patients with prostate cancer.

Progress in Prostate Cancer Options Creates Excitement

April 8th 2022

Prostate cancer is the most common cancer in men and the second-leading cause of cancer-related deaths in men in the US.

Phenotypic Biomarkers in the Management of Prostate Cancer

April 6th 2022

Expert perspectives on phenotypic biomarkers in prostate cancer and their role in comparison to genotypic biomarkers.

Factors in Selecting Novel AR-Targeted Therapy for Nonmetastatic CRPC

April 6th 2022

Comprehensive insight on selecting androgen receptor–targeted therapy for patients with nonmetastatic castration-resistant prostate cancer.

Background on Prostate Cancer and Biomarker Testing

April 6th 2022

Broad discussion on the role of biomarker testing in prostate cancer, particularly how it has helped to inform therapy selection and patient management.

Evolving Treatment Landscape of Nonmetastatic CRPC

April 6th 2022

Focusing on nonmetastatic castration-resistant prostate cancer, panelists review the current treatment armamentarium and shared decisionmaking.

Optimizing Use of PSMA PET Imaging and PSADT in Prostate Cancer

March 30th 2022

Shared insight on the respective roles of PSMA-PET imaging and PSA doubling time in the current prostate cancer treatment paradigm.

Overview of Improvements in Prostate Cancer Management

March 30th 2022

Broad discussion on the evolution of care in prostate cancer from both the therapeutic and imaging standpoints.